A key advantage of CAR-T therapy in treating hepatocellular carcinoma is that its efficacy does not rely on antigen presentation by major histocompatibility complex (MHC) molecules, thus circumventing MHC-related restrictions and addressing tumor immune escape issues due to MHC downregulation (79). This evidence concerns the gene HLA-C and hepatocellular carcinoma.